Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 1.00 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.72 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.72 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.72 |
| ▸ | MECP2 | P51608 | 1/20 | 0.72 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 8/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.65 |
| ▸ | RELA | Q04206 | 5/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | XBP1 | P17861 | 1/20 | 0.65 |
| ▸ | AHR | P35869 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30518424 | 0.86 | SLC2A1 (0.76) | SLC2A1KCNN1KCNN2KCNN3MECP2 | |
| SCHEMBL27073997 | 0.86 | SLC2A1 (0.76) | SLC2A1KCNN1KCNN2KCNN3MECP2 | |
| SCHEMBL30745771 | 0.84 | KCNN1 (1.00) | SLC2A1KCNN1KCNN2KCNN3MECP2 | |
| SCHEMBL5155715 | 0.84 | KCNN1 (1.00) | SLC2A1KCNN1KCNN2KCNN3MECP2 | |
| SCHEMBL24358150 | 0.84 | SLC2A1 (0.73) | SLC2A1KCNN1KCNN2KCNN3MECP2 | |
| SCHEMBL6372841 | 0.84 | SLC2A1 (0.73) | SLC2A1KCNN1KCNN2KCNN3MECP2 | |
| SCHEMBL29601468 | 0.84 | SLC2A1 (0.73) | SLC2A1KCNN1KCNN2KCNN3MECP2 | |
| SCHEMBL6368664 | 0.84 | SLC2A1 (0.73) | SLC2A1KCNN1KCNN2KCNN3MECP2 | |
| SCHEMBL14742535 | 0.84 | SLC2A1 (1.00) | SLC2A1KCNN1KCNN2KCNN3MECP2 | |
| SCHEMBL15993612 | 0.84 | SLC2A1 (0.72) | SLC2A1KCNN1KCNN2KCNN3MECP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| WO-2014159938-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-1740155-A1 | POLYCYLIC THIAZOLES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005099673-A1 | POLYCYLIC THIAZOLES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050227989-A1 | Polycyclic thiazoles as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | AADAT, ABAT, AASDHPPT | SLC2A1 3688/4885KCNN1 4803/4885KCNN2 4756/4885 |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | ABAT, AADAT, AASDHPPT | SLC2A1 3456/4885KCNN1 4631/4885KCNN2 4533/4885 |
| US-20050227989-A1 | Polycyclic thiazoles as potassium ion channel modulators | KCNJ2, KCNA3, KCNN3 | SLC2A1 821/4885KCNN1 10/4885KCNN2 6/4885 |
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | AADAT, ABAT, AASDHPPT | SLC2A1 3688/4885KCNN1 4803/4885KCNN2 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.